{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:07:57Z","timestamp":1793725677145,"version":"4.6.1"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01235-7","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T07:53:18Z","timestamp":1741074798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Evolution of WHO diagnostic criteria in \u201cClassical Myeloproliferative Neoplasms\u201d compared with the International Consensus Classification"],"prefix":"10.1038","volume":"15","author":[{"given":"J\u00fcrgen","family":"Thiele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Michael","family":"Kvasnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Gianelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2160-9689","authenticated-orcid":false,"given":"Daniel A.","family":"Arber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-6327","authenticated-orcid":false,"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1660-7013","authenticated-orcid":false,"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"1235_CR1","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835\u201349.","journal-title":"J Clin Oncol"},{"key":"1235_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.thj.6200013","volume":"1","author":"NL Harris","year":"2000","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November, 1997. Hematol J. 2000;1:53\u201366.","journal-title":"Hematol J"},{"key":"1235_CR3","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292\u2013302.","journal-title":"Blood"},{"key":"1235_CR4","unstructured":"Jaffe ES, Stein H, Harris NL, Stein H, Vardiman JW WHO Classification of Tumours:Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001."},{"key":"1235_CR5","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. (4th Edition). International Agency for Research on Cancer: Lyon, France, 2008."},{"key":"1235_CR6","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. (Revised 4th Edition). International Agency for Research on Cancer: Lyon, France, 2017."},{"key":"1235_CR7","unstructured":"Akkari Y, Campbell PJ, Cree IA, Hochhaus A, Hodge JC, Kantarijan HM, et al. WHO Classification of Tumours Editorial Board. Haematolymphoid Tumours. WHO classification of tumours series, 5th: vol.11. Myeloid proliferations and neoplasms. Lyon (France): International Agency for Research on Cancer; 2024."},{"key":"1235_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","volume":"6","author":"W Dameshek","year":"1951","unstructured":"Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372\u20135.","journal-title":"Blood"},{"key":"1235_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-2141.2012.09179.x","volume":"158","author":"JT Reilly","year":"2012","unstructured":"Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012;158:453\u201371.","journal-title":"Br J Haematol"},{"key":"1235_CR10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/bjh.12985","volume":"167","author":"JT Reilly","year":"2014","unstructured":"Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A, et al. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. Br J Haematol. 2014;167:418\u201320.","journal-title":"Br J Haematol"},{"key":"1235_CR11","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/leu.2015.360","volume":"30","author":"H Gisslinger","year":"2016","unstructured":"Gisslinger H, Jeryczynski G, Gisslinger B, W\u00f6lfler A, Burgstaller SV, Buxhofer-Ausch V, et al. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia. 2016;30:1126\u201332.","journal-title":"Leukemia"},{"key":"1235_CR12","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1235_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8:15.","journal-title":"Blood Cancer J"},{"key":"1235_CR14","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"15","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. Blood. 2022;15:1200\u201328.","journal-title":"Blood"},{"key":"1235_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ajh.26751","volume":"98","author":"J Thiele","year":"2023","unstructured":"Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM, et al. The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol. 2023;98:166\u201379.","journal-title":"Am J Hematol"},{"key":"1235_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00428-022-03480-8","volume":"482","author":"U Gianelli","year":"2023","unstructured":"Gianelli U, Thiele J, Orazi A, Gangat N, Vannucchi AM, Tefferi A, et al. International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. Virchows Arch. 2023;482:53\u201368.","journal-title":"Virchows Arch"},{"key":"1235_CR17","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26008","volume":"95","author":"A Tefferi","year":"2021","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;95:1599\u2013613.","journal-title":"Am J Hematol"},{"key":"1235_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.beha.2014.07.004","volume":"27","author":"G Barosi","year":"2014","unstructured":"Barosi G. Essential thrombocythemia vs. early\/prefibrotic myelofibrosis: why does it matter. Best Pr Res Clin Haematol. 2014;27:129\u201340.","journal-title":"Best Pr Res Clin Haematol"},{"key":"1235_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/BF01013883","volume":"32","author":"J Thiele","year":"1976","unstructured":"Thiele J, Georgii A, Vykoupil KF. Ultrastructure of chronic megakaryocytic-granulocytic myelosis. Blut. 1976;32:433\u20138.","journal-title":"Blut"},{"key":"1235_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF00430654","volume":"389","author":"A Georgii","year":"1980","unstructured":"Georgii A, Vykoupil KF, Thiele J. Chronic megakaryocytic granulocytic myelosis-CMGM. A subtype of chronic myeloid leukemia. Virchows Arch A Pathol Anat Histol. 1980;389:253\u201368.","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"1235_CR21","first-page":"59","volume":"23","author":"A Georgii","year":"1979","unstructured":"Georgii A. Histopathology of bone marrow in human chronic leukemias. Haematol Blood Transfus. 1979;23:59\u201370.","journal-title":"Haematol Blood Transfus"},{"key":"1235_CR22","first-page":"155","volume":"6","author":"J Thiele","year":"1984","unstructured":"Thiele J, Funke S, Holgado S, Choritz H, Georgii A. Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia. Anal Quant Cytol. 1984;6:155\u201367.","journal-title":"Anal Quant Cytol"},{"key":"1235_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0344-0338(11)81008-3","volume":"186","author":"A Georgii","year":"1990","unstructured":"Georgii A, Vykoupil KF, Buhr T, Choritz H, D\u00f6hler U, Kaloutsi V, et al. Chronic myeloproliferative disorders in bone marrow biopsies. Pathol Res Pr. 1990;186:3\u201327.","journal-title":"Pathol Res Pr"},{"key":"1235_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0344-0338(11)80081-6","volume":"189","author":"T Buhr","year":"1993","unstructured":"Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pr. 1993;189:121\u201332.","journal-title":"Pathol Res Pr"},{"key":"1235_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3109\/10428199609074357","volume":"22","author":"A Georgii","year":"1996","unstructured":"Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma. 1996;22:15\u201329.","journal-title":"Leuk Lymphoma"},{"key":"1235_CR26","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0950-3536(98)80036-X","volume":"11","author":"A Georgii","year":"1998","unstructured":"Georgii A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol. 1998;11:721\u201349.","journal-title":"Baillieres Clin Haematol"},{"key":"1235_CR27","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0344-0338(88)80090-6","volume":"183","author":"J Thiele","year":"1988","unstructured":"Thiele J, Simon KG, Fischer R, Zankovich R. Follow-up studies with sequential bone marrow biopsies in chronic myeloid leukaemia and so-called primary (idiopathic) osteo-myelofibrosis. Evolution of histopathological lesions and clinical course in 40 patients. Pathol Res Pr. 1988;183:434\u201345.","journal-title":"Pathol Res Pr"},{"key":"1235_CR28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000205560","volume":"81","author":"J Thiele","year":"1989","unstructured":"Thiele J, Zankovich R, Steinberg T, Kremer B, Fischer R, Diehl V. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis - a critical evaluation of clinical and histomorphological data. Acta Haematol. 1989;81:192\u2013202.","journal-title":"Acta Haematol"},{"key":"1235_CR29","first-page":"429","volume":"9","author":"J Thiele","year":"1989","unstructured":"Thiele J, Steinberg T, Zankovich R, Fischer R. Primary myelofibrosis- osteomyelosclerosis (agnogenic myeloid metaplasia): correlation of clinical findings with bone marrow histopathology and prognosis. Anticancer Res. 1989;9:429\u201335.","journal-title":"Anticancer Res"},{"key":"1235_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/hon.2900070502","volume":"7","author":"J Thiele","year":"1989","unstructured":"Thiele J, Zankovich R, Steinberg T, Fischer R, Diehl V. Agnogenic myeloid metaplasia (AMM)-correlation of bone marrow lesions with laboratory data: a longitudinal clinicopathological study on 114 patients. Hematol Oncol. 1989;7:327\u201343.","journal-title":"Hematol Oncol"},{"key":"1235_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000205560","volume":"81","author":"J Thiele","year":"1989","unstructured":"Thiele J, Zankovich R, Steinberg T, Kremer B, Fischer R, Diehl V. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis-a critical evaluation of clinical and histomorphological data. Acta Haematol. 1989;81:192\u2013202.","journal-title":"Acta Haematol"},{"key":"1235_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3109\/10428199209053572","volume":"6","author":"J Thiele","year":"1992","unstructured":"Thiele J, Kvasnicka HM, Steinberg T, Zankovich R, Fischer R, Diehl V. Survival in primary (idiopathic osteomyelofibrosis, so-called agnogenic myeloid metapalsia. Leuk Lymphoma. 1992;6:389\u201399.","journal-title":"Leuk Lymphoma"},{"key":"1235_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3109\/10428199609051762","volume":"22","author":"J Thiele","year":"1996","unstructured":"Thiele J, Kvasnicka HM, Werden C, Zankovich R, Diehl V, Fischer R. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma. 1996;22:303\u201317.","journal-title":"Leuk Lymphoma"},{"key":"1235_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3109\/10428199909058421","volume":"33","author":"J Thiele","year":"1999","unstructured":"Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels J. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma. 1999;33:207\u2013118.","journal-title":"Leuk Lymphoma"},{"key":"1235_CR35","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1038\/sj.leu.2401553","volume":"13","author":"J Thiele","year":"1999","unstructured":"Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study. Leukemia. 1999;13:1741\u20138.","journal-title":"Leukemia"},{"key":"1235_CR36","first-page":"183","volume":"23","author":"LR Wasserman","year":"1986","unstructured":"Wasserman LR. Polycythemia Vera Study Group: a historical perspective. Semin Hematol. 1986;23:183\u20137.","journal-title":"Semin Hematol"},{"key":"1235_CR37","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"1235_CR38","first-page":"29","volume":"34","author":"S Murphy","year":"1997","unstructured":"Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34:29\u201339.","journal-title":"Semin Hematol"},{"key":"1235_CR39","first-page":"9","volume":"36","author":"S Murphy","year":"1999","unstructured":"Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol. 1999;36:9\u201313.","journal-title":"Semin Hematol"},{"key":"1235_CR40","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00277-002-0604-y","volume":"82","author":"J Thiele","year":"2003","unstructured":"Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol. 2003;82:148\u201352.","journal-title":"Ann Hematol"},{"key":"1235_CR41","first-page":"911","volume":"89","author":"AM Florena","year":"2004","unstructured":"Florena AM, Tripodo C, Iannitto E, Porcasi R, Ingrao S, Franco V. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica. 2004;89:911\u20139.","journal-title":"Haematologica"},{"key":"1235_CR42","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1080\/10428190600678975","volume":"47","author":"U Gianelli","year":"2006","unstructured":"Gianelli U, Vener C, Raviele PR, Moro A, Savi F, Annaloro C, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma. 2006;47:1774\u201381.","journal-title":"Leuk Lymphoma"},{"key":"1235_CR43","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1055\/s-2006-942757","volume":"32","author":"HM Kvasnicka","year":"2006","unstructured":"Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost. 2006;32:362\u201371.","journal-title":"Semin Thromb Hemost"},{"key":"1235_CR44","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, Van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128\u201332.","journal-title":"Haematologica"},{"key":"1235_CR45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1179\/1607845412Y.0000000023","volume":"18","author":"E Ejerblad","year":"2013","unstructured":"Ejerblad E, Kvasnicka HM, Thiele J, Andreasson B, Bj\u00f6rkholm M, L\u00f6fvenberg E, et al. Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up. Hematology. 2013;18:8\u201313.","journal-title":"Hematology"},{"key":"1235_CR46","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/his.12871","volume":"68","author":"HM Kvasnicka","year":"2016","unstructured":"Kvasnicka HM, Beham-Schmid C, Bob R, Dirnhofer S, Hussein K, Kreipe H, et al. Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study. Histopathology. 2016;68:905\u201315.","journal-title":"Histopathology"},{"key":"1235_CR47","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","volume":"7","author":"J Thiele","year":"2011","unstructured":"Thiele J, Kvasnicka HM, Mullauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;7:5710\u20138.","journal-title":"Blood"},{"key":"1235_CR48","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092\u2013927.","journal-title":"Blood"},{"key":"1235_CR49","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384.","journal-title":"J Clin Oncol"},{"key":"1235_CR50","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/ajh.23554","volume":"88","author":"AB Madelung","year":"2013","unstructured":"Madelung AB, Bondo H, Stamp I, Loevgreen P, Nielsen SL, Falensteen A, et al. World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations\u2014the Danish experience. Am J Hematol. 2013;88:1012\u20136.","journal-title":"Am J Hematol"},{"key":"1235_CR51","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, et al. thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121:1720\u20138.","journal-title":"Blood"},{"key":"1235_CR52","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/modpathol.2013.196","volume":"27","author":"U Gianelli","year":"2014","unstructured":"Gianelli U, Bossi A, Cortinovis I, Sabattini E, Tripodo C, Boveri E, et al. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Mod Pathol. 2014;27:814\u201322.","journal-title":"Mod Pathol"},{"key":"1235_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","volume":"111","author":"BS Wilkins","year":"2008","unstructured":"Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111:60\u201370.","journal-title":"Blood"},{"key":"1235_CR54","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/j.1365-2559.2010.03545.x","volume":"56","author":"M Brousseau","year":"2010","unstructured":"Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology. 2010;56:758\u201367.","journal-title":"Histopathology"},{"key":"1235_CR55","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1309\/AJCP2UG9SGGWAHUA","volume":"136","author":"SM Koopmans","year":"2011","unstructured":"Koopmans SM, Bot FJ, Lam KH, van Marion AM, de Raeve H, Hebeda KM. Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia. Am J Clin Pathol. 2011;136:618\u201324.","journal-title":"Am J Clin Pathol"},{"key":"1235_CR56","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2011.047811","volume":"97","author":"T Buhr","year":"2012","unstructured":"Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97:360\u20135.","journal-title":"Haematologica"},{"key":"1235_CR57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11899-009-0005-6","volume":"4","author":"J Thiele","year":"2009","unstructured":"Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep. 2009;4:33\u201340.","journal-title":"Curr Hematol Malig Rep."},{"key":"1235_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00972-x","volume":"14","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Al-Kali A, Begna KH, Elliott MA, Wolanskyj-Spinner AP, et al. One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood Cancer J. 2024;14:11.","journal-title":"Blood Cancer J"},{"key":"1235_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00968-7","volume":"14","author":"GG Loscocco","year":"2024","unstructured":"Loscocco GG, Gesullo F, Capecchi G, Atanasio A, Maccari C, Mannelli F, et al. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. Blood Cancer J. 2024;14:10.","journal-title":"Blood Cancer J"},{"key":"1235_CR60","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/(SICI)1096-8652(199711)56:3<168::AID-AJH6>3.0.CO;2-W","volume":"56","author":"A Regev","year":"1997","unstructured":"Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol. 1997;56:168\u201372.","journal-title":"Am J Hematol"},{"key":"1235_CR61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1365-2141.1998.00529.x","volume":"100","author":"E Lengfelder","year":"1998","unstructured":"Lengfelder E, Hochhaus A, Kronawitter U, H\u00f6che D, Queisser W, Jahn-Eder M, et al. Should a platelet limit of 600 x 109\/L be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol. 1998;100:15\u201323.","journal-title":"Br J Haematol"},{"key":"1235_CR62","first-page":"492","volume":"85","author":"S Sacchi","year":"2000","unstructured":"Sacchi S, Vinci G, Gugliotta L, Rupoli S, Gargantini L, Martinelli V, et al. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600 x 109\/L. Gruppo Italiano Malattie Mieloproliferative Croniche (GIMMC). Haematologica. 2000;85:492\u201358.","journal-title":"Haematologica"},{"key":"1235_CR63","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","volume":"149","author":"CN Harrison","year":"2010","unstructured":"Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010;149:352\u201375.","journal-title":"Br J Haematol"},{"key":"1235_CR64","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/bjh.12986","volume":"167","author":"CN Harrison","year":"2014","unstructured":"Harrison CN, Butt N, Campbell P, Conneally E, Drummond M, Green AR, et al. Modification of British committee for standards in J Haematol haematology diagnostic criteria for essential thrombocythaemia. Br J Hematol 2014;167:421\u20133.","journal-title":"Br J Hematol"},{"key":"1235_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.64","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J. 2015;5:e337.","journal-title":"Blood Cancer J"},{"key":"1235_CR66","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","volume":"189","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189:291\u2013302.","journal-title":"Br J Haematol"},{"key":"1235_CR67","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507\u201313.","journal-title":"Blood"},{"key":"1235_CR68","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","volume":"381","author":"A Tefferi","year":"2019","unstructured":"Tefferi A, Pardanani A. Essential Thrombocythemia. N. Engl J Med. 2019;381:2135\u201344.","journal-title":"N. Engl J Med"},{"key":"1235_CR69","doi-asserted-by":"publisher","first-page":"e578","DOI":"10.1097\/HS9.0000000000000578","volume":"5","author":"SN Constantinescu","year":"2021","unstructured":"Constantinescu SN, Vainchenker W, Levy G, Papadopoulos N. Functional consequences of mutations in myeloproliferative neoplasms. Hemasphere. 2021;5:e578.","journal-title":"Hemasphere"},{"key":"1235_CR70","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/ajh.26332","volume":"96","author":"GG Loscocco","year":"2021","unstructured":"Loscocco GG, Guglielmelli P, Gangat N, Rossi E, Mannarelli C, Betti S, et al. Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. Am J Hematol. 2021;96:1472\u201380.","journal-title":"Am J Hematol"},{"key":"1235_CR71","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.27216","volume":"99","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99:697\u2013718.","journal-title":"Am J Hematol"},{"key":"1235_CR72","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, et al. Differential clinical effects of different mutation subtypes in CALR\u2010mutant myeloproliferative neoplasms. Leukemia. 2016;30:431\u20138.","journal-title":"Leukemia"},{"key":"1235_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18691-3","volume":"11","author":"C Benlabiod","year":"2020","unstructured":"Benlabiod C, Cacemiro MdC, Nedelec A, Edmond D, Muller D, Rameau P, et al. Calreticulin del52 and ins5 knock\u2010in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN. Nat Commun. 2020;11:4886.","journal-title":"Nat Commun"},{"key":"1235_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00639-z","volume":"12","author":"N Gangat","year":"2022","unstructured":"Gangat N, Jadoon Y, Szuber N, Hanson CA, Wolanskyj-Spinner AP, Ketterling RP, et al. Cytogenetic abnormalities in essential thrombocythemia: clinical and molecular correlates and prognostic relevance in 809 informative cases. Blood Cancer J. 2022;12:44.","journal-title":"Blood Cancer J"},{"key":"1235_CR75","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21\u201330.","journal-title":"Blood Adv"},{"key":"1235_CR76","doi-asserted-by":"publisher","first-page":"101735","DOI":"10.18632\/oncotarget.21594","volume":"8","author":"E Rumi","year":"2017","unstructured":"Rumi E, Boveri E, Bellini M, Pietra D, Ferretti VV, Sant\u2019Antonio E, et al. Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget. 2017;8:101735\u201344.","journal-title":"Oncotarget"},{"key":"1235_CR77","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ajh.24882","volume":"92","author":"A Tefferi","year":"2017","unstructured":"Tefferi A, Betti S, Barraco D, Mudireddy M, Shah S, Hanson CA, et al. Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. Am J Hematol. 2017;92:1193\u20137.","journal-title":"Am J Hematol"},{"key":"1235_CR78","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/ejh.12873","volume":"98","author":"K Abdulkarim","year":"2017","unstructured":"Abdulkarim K, Samuelsson J, Johansson P, Andr\u00e9asson B. Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry. Eur J Haematol. 2017;98:577\u201383.","journal-title":"Eur J Haematol"},{"key":"1235_CR79","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/ajh.24788","volume":"92","author":"G Jeryczynski","year":"2017","unstructured":"Jeryczynski G, Thiele J, Gisslinger B, Wolfler A, Schalling M, Glei\u00df A, et al. Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 2017;92:885\u201391.","journal-title":"Am J Hematol"},{"key":"1235_CR80","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, et al. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clin Proc. 2019;94:599\u2013610.","journal-title":"Mayo Clin Proc"},{"key":"1235_CR81","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","volume":"129","author":"P Guglielmelli","year":"2017","unstructured":"Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129:3227\u201336.","journal-title":"Blood"},{"key":"1235_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00368-1","volume":"10","author":"A Carobbio","year":"2020","unstructured":"Carobbio A, Guglielmelli P, Rumi E, Cavalloni C, De Stefano V, Betti S, et al. A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. Blood Cancer J. 2020;10:100.","journal-title":"Blood Cancer J"},{"key":"1235_CR83","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874\u201381.","journal-title":"Leukemia"},{"key":"1235_CR84","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000084673","volume":"113","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol. 2005;113:213\u20139.","journal-title":"Acta Haematol"},{"key":"1235_CR85","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1309\/6BQ5K8LHVYAKUAF4","volume":"30","author":"U Gianelli","year":"2008","unstructured":"Gianelli U, Iurlo A, Vener C, Moro A, Fermo E, Bianchi P, et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the \u201cearly\u201d prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol. 2008;30:336\u201342.","journal-title":"Am J Clin Pathol"},{"key":"1235_CR86","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"9","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;9:1465\u201387.","journal-title":"Am J Hematol"},{"key":"1235_CR87","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00277-018-3344-3","volume":"97","author":"L Jakovic","year":"2018","unstructured":"Jakovic L, Gotic M, Gisslinger H, Soldatovic I, Sefer D, Tirnanic M, et al. The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin\/hematocrit level and morphology. Ann Hematol. 2018;97:1581\u201390.","journal-title":"Ann Hematol"},{"key":"1235_CR88","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1182\/blood-2007-12-128454","volume":"112","author":"JL Spivak","year":"2008","unstructured":"Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112:231\u20139.","journal-title":"Blood"},{"key":"1235_CR89","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/leu.2014.35","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Thiele J, Vardiman J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014;28:1407\u201313.","journal-title":"Leukemia"},{"key":"1235_CR90","first-page":"1194","volume":"89","author":"P Mossuz","year":"2004","unstructured":"Mossuz P, Girodon F, Donnard M, Latger-Cannard V, Dobo I, Boiret N, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89:1194\u20138.","journal-title":"Haematologica"},{"key":"1235_CR91","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.patbio.2006.06.002","volume":"55","author":"JJ Michiels","year":"2007","unstructured":"Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). Pathol Biol (Paris). 2007;55:92\u2013104.","journal-title":"Pathol Biol (Paris)"},{"key":"1235_CR92","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/ajh.24684","volume":"92","author":"T Barbui","year":"2017","unstructured":"Barbui T, Thiele J, Gisslinger H, Carobbio A, Vannucchi AM, Tefferi A. Diagnostic impact of the 2016 revised WHO criteria for polycythemia vera. Am J Hematol. 2017;92:417\u20139.","journal-title":"Am J Hematol"},{"key":"1235_CR93","first-page":"317","volume":"20","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol. 2005;20:317\u201328.","journal-title":"Histol Histopathol"},{"key":"1235_CR94","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1182\/blood-2013-06-508416","volume":"122","author":"RT Silver","year":"2013","unstructured":"Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood. 2013;122:1881\u20136.","journal-title":"Blood"},{"key":"1235_CR95","first-page":"1881","volume":"122","author":"U Gianelli","year":"2014","unstructured":"Gianelli U, Iurlo A, Cattaneo D, Lambertenghi-Deliliers G. Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood. 2014;122:1881\u20136.","journal-title":"Blood"},{"key":"1235_CR96","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","volume":"35","author":"A Tefferi","year":"2021","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021;35:3339\u201351.","journal-title":"Leukemia"},{"key":"1235_CR97","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3324\/haematol.2017.165795","volume":"102","author":"G Tang","year":"2017","unstructured":"Tang G, Hidalgo Lopez JE, Wang SA, Hu S, Ma J, Pierce S, et al. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica. 2017;102:1511\u20138.","journal-title":"Haematologica"},{"key":"1235_CR98","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjh.14798","volume":"182","author":"D Barraco","year":"2018","unstructured":"Barraco D, Cerquozzi S, Hanson CA, Ketterling RP, Pardanani A, Gangat N, et al. Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. Br J Haematol. 2018;182:437\u201340.","journal-title":"Br J Haematol"},{"key":"1235_CR99","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ajh.23694","volume":"89","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Carobbio A, Guglielmelli P, Rambaldi A, Vannucchi AM, et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. Am J Hematol. 2014;89:588\u201390.","journal-title":"Am J Hematol"},{"key":"1235_CR100","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/leu.2013.380","volume":"28","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rethinking the diagnostic criteria of polycythemia vera. Leukemia. 2014;28:1191\u20135.","journal-title":"Leukemia"},{"key":"1235_CR101","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1751-553X.2008.01102.x","volume":"30","author":"MF McMullin","year":"2008","unstructured":"McMullin MF. The classification and diagnosis of erythrocytosis. Int J Lab Hematol. 2008;30:447\u201359.","journal-title":"Int J Lab Hematol"},{"key":"1235_CR102","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ajh.23585","volume":"89","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014;89:52\u20134. Erratum in: Am J Hematol. 2018;93:E133","journal-title":"Am J Hematol"},{"key":"1235_CR103","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ajh.23617","volume":"89","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Carobbio A, Gisslinger H, Finazzi G, Rumi E, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol. 2014;89:199\u2013202.","journal-title":"Am J Hematol"},{"key":"1235_CR104","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ejh.12552","volume":"96","author":"A Alvarez-Larr\u00e1n","year":"2016","unstructured":"Alvarez-Larr\u00e1n A, Angona A, Ancochea A, Garc\u00eda-Pallarols F, Fern\u00e1ndez C, Longar\u00f3n R, et al. Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes. Eur J Haematol. 2016;96:83\u20139.","journal-title":"Eur J Haematol"},{"key":"1235_CR105","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/ajh.24837","volume":"92","author":"HM Kvasnicka","year":"2017","unstructured":"Kvasnicka HM, Orazi A, Thiele J, Barosi G, Bueso-Ramos CE, Vannucchi AM, et al. European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. Am J Hematol. 2017;92:1062\u20137.","journal-title":"Am J Hematol"},{"key":"1235_CR106","doi-asserted-by":"publisher","first-page":"E128","DOI":"10.1002\/ajh.24752","volume":"92","author":"K Misawa","year":"2017","unstructured":"Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Nudejima M, et al. The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: comparison with the 2008 WHO diagnostic criteria. Am J Hematol. 2017;92:E128\u2013E130.","journal-title":"Am J Hematol"},{"key":"1235_CR107","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","volume":"119","author":"T Barbui","year":"2012","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012;119:2239\u201341.","journal-title":"Blood"},{"key":"1235_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.17","volume":"7","author":"D Barraco","year":"2017","unstructured":"Barraco D, Cerquozzi S, Hanson CA, Ketterling RP, Pardanani A, Gangat N, et al. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. Blood Cancer J. 2017;7:e538.","journal-title":"Blood Cancer J"},{"key":"1235_CR109","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437\u20138.","journal-title":"Leukemia"},{"key":"1235_CR110","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1182\/blood-2017-04-777805","volume":"129","author":"H Gisslinger","year":"2017","unstructured":"Gisslinger H. Pre-PMF emerging as important subgroup of MPN. Blood. 2017;129:3142\u20134.","journal-title":"Blood"},{"key":"1235_CR111","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00277-005-0042-8","volume":"85","author":"J Thiele","year":"2006","unstructured":"Thiele J, Kvasnicka HM. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol. 2006;85:226\u201332.","journal-title":"Ann Hematol"},{"key":"1235_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0006-y","volume":"7","author":"M Schalling","year":"2017","unstructured":"Schalling M, Gleiss A, Gisslinger B, W\u00f6lfler A, Buxhofer-Ausch V, Jeryczynskiet G, et al. Essential thrombocythemia vs. pre-fibrotic\/early primary myelofibrosis: discrimination by laboratory and clinical data. Blood Cancer J. 2017;7:643.","journal-title":"Blood Cancer J"},{"key":"1235_CR113","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/bjh.14838","volume":"182","author":"M Mudireddy","year":"2018","unstructured":"Mudireddy M, Shah S, Lasho T, Barraco D, Hanson CA, Ketterling RP, et al. Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. Br J Haematol. 2018;182:594\u20137.","journal-title":"Br J Haematol"},{"key":"1235_CR114","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s12185-018-2495-2","volume":"108","author":"A Kamiunten","year":"2018","unstructured":"Kamiunten A, Shide K, Kameda T, Ito M, Sekine M, Kabuki Y, et al. Early\/prefibrotic primary myelofibrosis in patients WHO were initially diagnosed with essential thrombocythemia. Int J Hematol. 2018;108:411\u20135.","journal-title":"Int J Hematol"},{"key":"1235_CR115","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjh.15562","volume":"183","author":"N Curto-Garcia","year":"2018","unstructured":"Curto-Garcia N, Ianotto JC, Harrison CN. What is pre-fibrotic myelofibrosis and how should it be managed in 2018? Br J Haematol. 2018;183:23\u201334.","journal-title":"Br J Haematol"},{"key":"1235_CR116","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/ejh.13041","volume":"100","author":"T Ochiai","year":"2018","unstructured":"Ochiai T, Yasuda H, Araki M, Misawa K, Morishita S, Nudejima M, et al. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort. Eur J Haematol. 2018;100:544\u20139.","journal-title":"Eur J Haematol"},{"key":"1235_CR117","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.3390\/cancers15164180","volume":"15","author":"D Lekovic","year":"2023","unstructured":"Lekovic D, Bogdanovic A, Sobas M, Arsenovic I, Smiljanic M, Ivanovic J, et al. Easily applicable predictive score for differential diagnosis of prefibrotic primary myelofibrosis from essential thrombocythemia. Cancers (Basel). 2023;15:4180.","journal-title":"Cancers (Basel)"},{"key":"1235_CR118","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/ajh.25270","volume":"93","author":"N Szuber","year":"2018","unstructured":"Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018;93:1474\u201384.","journal-title":"Am J Hematol"},{"key":"1235_CR119","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ajh.25230","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93:1551\u201360.","journal-title":"Am J Hematol"},{"key":"1235_CR120","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:801\u201321.","journal-title":"Am J Hematol"},{"key":"1235_CR121","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1182\/blood-2007-09-112953","volume":"111","author":"C Vener","year":"2008","unstructured":"Vener C, Fracchiolla NS, Gianelli U, Calori R, Radaelli F, Iurlo A, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood. 2008;111:1862\u20135.","journal-title":"Blood"},{"key":"1235_CR122","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/modpathol.2012.87","volume":"25","author":"U Gianelli","year":"2012","unstructured":"Gianelli U, Vener C, Bossi A, Cortinovis I, Iurlo A, Fracchiolla NS, et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol. 2012;25:1193\u2013202.","journal-title":"Mod Pathol"},{"key":"1235_CR123","first-page":"E454","volume":"91","author":"P Guglielmelli","year":"2016","unstructured":"Guglielmelli P, Vannucchi AM, Investigators A. The prognostic impact of bone marrow fibrosis in primary myelofibrosis. Am J Hematol. 2016;91:E454\u2013E455.","journal-title":"Am J Hematol"},{"key":"1235_CR124","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1046\/j.1365-2141.1999.01262.x","volume":"104","author":"G Barosi","year":"1999","unstructured":"Barosi G, Ambrosetti A, Finelli C, Grossi A, Leoni P, Liberato NL, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104:730\u20137.","journal-title":"Br J Haematol"},{"key":"1235_CR125","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","volume":"342","author":"A Tefferi","year":"2000","unstructured":"Tefferi A. Myelofibrosis with Myeloid Metaplasia. N. Engl J Med. 2000;342:1255\u201365.","journal-title":"N. Engl J Med"},{"key":"1235_CR126","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","volume":"23","author":"A Tefferi","year":"2005","unstructured":"Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23:8520\u201330.","journal-title":"J Clin Oncol"},{"key":"1235_CR127","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Mudireddy M, Lasho TL, Gangat N, Begna KH, et al. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia. 2018;32:1189\u201399.","journal-title":"Leukemia"},{"key":"1235_CR128","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl J Med. 2005;353:33\u201345.","journal-title":"N. Engl J Med"},{"key":"1235_CR129","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","volume":"30","author":"M Hultcrantz","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30:2995\u20133001.","journal-title":"J Clin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01235-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01235-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01235-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T08:27:57Z","timestamp":1741076877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01235-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":129,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01235-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"29 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}